Ironwood Pharmaceuticals (NASDAQ:IRWD) Issues Earnings Results

Ironwood Pharmaceuticals (NASDAQ:IRWD) released its quarterly earnings results on Thursday. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01), FiscalAI reports. The firm had revenue of $113.04 million for the quarter, compared to analyst estimates of $114.84 million. Ironwood Pharmaceuticals had a negative return on equity of 58.38% and a net margin of 33.36%.

Here are the key takeaways from Ironwood Pharmaceuticals’ conference call:

• LINZESS delivered strong momentum: Q2 U.S. net sales rose 14% year over year to $282.3 million, supported by mid-single-digit prescription growth and improved net pricing. Ironwood raised its 2026 LINZESS sales outlook to $1.15 billion–$1.20 billion, implying growth of more than 30% and a return to blockbuster status.
• The FDA approved LINZESS for functional constipation in pediatric patients aged two and older, making it the only prescription therapy approved for this age group and expanding the brand’s addressable patient population.
• Ironwood initiated active enrollment in the confirmatory Phase III STARS-2 trial for apraglutide in short bowel syndrome with intestinal failure. Management believes the once-weekly therapy’s efficacy, tolerability, and potential to reduce parenteral-support dependence could support a best-in-class profile, though enrollment remains an execution priority.
• Q2 GAAP net income was $51 million and adjusted EBITDA was $83 million; full-year revenue guidance increased to $460 million–$485 million and adjusted EBITDA guidance to above $310 million. The company repaid $200 million of convertible notes and expects gross debt below $300 million and leverage below 1x by year-end.
• R&D spending is expected to rise in the second half as STARS-2 enrollment and site activation ramp, with modestly higher SG&A also anticipated. The ultimate expense increase will depend on how quickly additional trial sites are brought online.

Ironwood Pharmaceuticals Stock Up 1.4%

Shares of IRWD traded up $0.06 during mid-day trading on Friday, hitting $4.32. The company had a trading volume of 1,842,560 shares, compared to its average volume of 2,179,845. Ironwood Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $5.78. The business’s 50-day simple moving average is $3.90 and its 200-day simple moving average is $3.97. The stock has a market cap of $704.41 million, a PE ratio of 5.61 and a beta of 0.20.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, insider Ronald Silver sold 127,890 shares of the stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total transaction of $578,062.80. Following the transaction, the insider owned 313,680 shares of the company’s stock, valued at $1,417,833.60. This trade represents a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Julie Mchugh sold 21,571 shares of Ironwood Pharmaceuticals stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total transaction of $80,459.83. Following the completion of the transaction, the director owned 250,749 shares in the company, valued at approximately $935,293.77. This trade represents a 7.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 9.30% of the company’s stock.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 21.4% in the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,406 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its stake in shares of Ironwood Pharmaceuticals by 7.8% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 76,951 shares of the biotechnology company’s stock valued at $259,000 after acquiring an additional 5,598 shares during the period. Public Employees Retirement System of Ohio raised its holdings in Ironwood Pharmaceuticals by 11.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 67,888 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 7,120 shares in the last quarter. Focus Partners Advisor Solutions LLC lifted its position in Ironwood Pharmaceuticals by 14.0% in the fourth quarter. Focus Partners Advisor Solutions LLC now owns 59,617 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 7,322 shares during the period. Finally, Rhumbline Advisers lifted its position in Ironwood Pharmaceuticals by 3.5% in the third quarter. Rhumbline Advisers now owns 223,229 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 7,611 shares during the period.

Wall Street Analysts Forecast Growth

IRWD has been the subject of several recent analyst reports. Wall Street Zen cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research note on Friday, July 24th. Finally, Zacks Research cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Ironwood Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial?stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.